ASX Top Gainers: What's Driving VGL SKY and NYR
Written by
Varun Ratra
ASX companies Vista, SKY Metals and Nyrada reported major agreements, drilling results, drug trials progress and recent updates on patent developments.
Vista Group International Ltd (ASX: VGL)
Vista Group International Ltd on 20 May 2026 announced that Cinepolis signed a six year agreement to move its Mexico circuit to Vista Cloud Operational Excellence. Cinepolis operates 504 cinema sites with more than 4,100 screens across Mexico. The transition is planned through 2026 while commercial terms began from 1 January 2026. The agreement also includes all Vista Cloud capabilities.
The company showed that this development came after the earlier migration of Cine Yelmo in Spain during 2024 and 2025. Cine Yelmo had already shifted to Vista Cloud Digital Enablement and later adopted Operational Excellence capabilities. The progress of that project supported the next phase with the larger Mexico circuit.
On 14 May 2026, Vista Group International Ltd announced that Regal Cineworld Group signed for Digital Enablement across 88 UK cinema sites with more than 950 screens. The rollout is planned for 2026 after the successful transition of 25 Picturehouse Cinemas sites in 2025.
SKY Metals Ltd (ASX: SKY)
on 18 May 2026 reported more wide and shallow high grade tin, tungsten and silver intercepts from infill drilling at the Tallebung Project. The results are expected to support the updated Mineral Resource Estimate and Pre Feasibility Study planned for release this quarter. More than 500 drill holes have now been completed at the project.
The company noted that recent drilling targeted shallow high grade zones for potential early mine production. Additional assay results from infill and extensional drilling are still pending and may support further resource growth. The ongoing program is focused on advancing Tallebung toward near term development and production opportunities.
SKY declared on 14 May 2026 that it has entered into a binding option contract with Locksley Resources Limited to divest the non core Iron Duke Copper Gold Project in New South Wales for a total potential value of $1.1M. The deal contains upfront cash payments and milestone linked consideration.
Nyrada Inc (ASX: NYR)
on 20 May 2026 announced that Xolatryp showed anti tumour activity in a preclinical liver cancer study. The drug reduced tumour volume both on its own and in combination with doxorubicin. The combined treatment delivered the strongest result and was well tolerated. The company also lodged a provisional patent application covering Xolatryp as an anti cancer treatment.
On 19 May 2026, NYR received a notice of allowance from the United States Patent and the Trademark Office for its Xolatryp composition of matter patent application. The patent is likely to provide protection in the United States for 20 years from the September 2024 filing date. The application is also part of a broader patent portfolio across Australia, Europe and Japan.
On 22 April 2026, the first hospital site opened for recruitment in the PROTECT-MI Phase IIa trial. The study is testing Xolatryp for reducing heart muscle injury after a heart attack.
(Source: Company Report)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
